retatrutide trial news today Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In The numbers from Lilly's Phase

Collaborative Network, comprising 68 healthcare organizations, who were diagnosed with breast cancer between April 2006 and April 2023

Most people coping with metabolic obesity are familiar with its health risks: high blood pressure, dysregulated blood sugar, metabolically active abdominal fat, and elevated cholesterol and triglyceride levels

Resistant potato starch is a type of starch that the small intestine cannot digest - it passes intact to the colon, where gut bacteria ferment it into short-chain fatty acids

Kloner, R

Clinical studies continue to increase, yet the dermatological effects of these treatments remain poorly understood and lack adequate characterization

Zepbound is available in the following strengths as single-dose pens or vials: 2.5 mg/0.5 mL 5 mg/0.5 mL 7.5 mg/0.5 mL 10 mg/0.5 mL 12.5 mg/0.5 mL 15 mg/0.5 mL Zepbound KwikPen (single-patient-use) or multi-dose vial, each containing 4 doses, are approved by the FDA in the following strengths: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg /0.6 mL doses 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg /0.6 mL doses 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg /0.6 mL doses 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg /0.6 mL doses 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg /0.6 mL doses 60 mg/2.4 mL (25 mg/mL) for four 15 mg /0.6 mL doses What strengths are Mounjaro pens